<DOC>
	<DOCNO>NCT00701129</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , clinical benefit safety prophylactic immunomodulatory regimen give prior first treatment alglucosidase alfa ( Myozyme® ) patient infantile-onset Pompe disease . The objective assess efficacy prophylactic immunomodulatory regimen give prior first treatment alglucosidase alfa , assess anti-recombinant human acid alpha-glucosidase ( anti-rhGAA ) antibody titer , antibody inhibit activity and/or uptake alglucosidase alfa ; evaluate clinical benefit measure overall survival , ventilator-free survival , leave ventricular mass index ( LVMI ) , gross motor function development , disability index incidence adverse event ( AEs ) , serious adverse event ( SAEs ) , clinical laboratory abnormality .</brief_summary>
	<brief_title>An Exploratory Study Safety Efficacy Prophylactic Immunomodulatory Treatment Myozyme-naive Cross-Reacting Immunologic Material ( CRIM- ) Patients With Infantile-Onset Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>The patient 's legal guardian ( ) must provide write informed consent prior studyrelated procedure perform The patient must clinical diagnosis Pompe disease define documented acid alphaglucosidase ( GAA ) deficiency ( deficient endogenous GAA activity ) skin fibroblast , muscle , blood , 2 GAA mutation . Consent also seek biological parent ( ) parental GAA mutational analysis , requirement study eligibility The patient must receive Myozyme® rhGAA therapy prior enrollment study The patient must CRIM negative via Western Blot analysis perform skin fibroblast via 2 known CRIM negative mutation ( case CRIM status confirm Western Blot analysis enrollment ) The patient 's legal guardian ( ) must ability comply clinical protocol The patient medical condition , opinion Investigator , could exacerbated/precipitated interfere study regimen assessment ; condition may include limited human immunodeficiency virus , cancer , Hepatitis B , Hepatitis C , Cytomegalovirus , Herpes Simplex , John Cunningham ( JC ) virus , Parvovirus , Epstein Barr virus tuberculosis The patient use investigational product within 30 day prior study enrollment The patient require live vaccination within 1 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Glycogenesis 2</keyword>
	<keyword>Acid</keyword>
	<keyword>Maltase</keyword>
	<keyword>Deficiency</keyword>
</DOC>